List view / Grid view
New real-world evidence from a long-term follow up study adds…
New real-world evidence from a long-term follow up study adds to evidence of the high efficacy of Beyfortus in infant RSV.
A potential first-in-class extraintestinal pathogenic E. coli (ExPEC) vaccine set…
A potential first-in-class extraintestinal pathogenic E. coli (ExPEC) vaccine set to be jointly developed by Sanofi and Janssen, could help to abate a pathogen that is key in driving global antimicrobial resistance (AMR).
The only monoclonal antibody approved for passive immunisation to protect…
The only monoclonal antibody approved for passive immunisation to protect infants in their first RSV season has been approved by the US Food and Drug Administration (FDA).
New real-world data “adds to the evidence that use of…
New real-world data “adds to the evidence that use of long-acting monoclonal antibody [nirsevimab] may prevent moderate to severe respiratory syncytial virus disease” in infants after single dose.
The Biologics License Application for nirsevimab as the first protective…
The Biologics License Application for nirsevimab as the first protective option against RSV for all infants has been accepted by the the US Food and Drug Administration (FDA).
The facility is designed around a central unit that comprises…
The facility is designed around a central unit that comprises several fully digitalised modules, which can produce up to four vaccines simultaneously, regardless of the vaccine technology used.
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying…
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
Sanofi has entered into an agreement to acquire Origimm Biotechnology…
Sanofi has entered into an agreement to acquire Origimm Biotechnology to add a potential first-in-class vaccine for acne to their pipeline.
The dose finding study will assess the safety, reactogenicity and…
The dose finding study will assess the safety, reactogenicity and immunogenicity of the companies’ investigational COVID-19 vaccine in 720 participants.
MenQuadfi® has been approved for use in individuals 12 months…
MenQuadfi® has been approved for use in individuals 12 months of age and older, based on its safety and immunogenicity in 6,300 trial subjects.
Sanofi and GSK have agreed to support the COVID-19 vaccine…
Sanofi and GSK have agreed to support the COVID-19 vaccine (COVAX) Facility with 200 million doses of their adjuvanted, recombinant protein-based COVID-19 vaccine.
Sanofi and GSK have reached an agreement with the UK…
Sanofi and GSK have reached an agreement with the UK government to supply up to 60 million doses of their COVID-19 vaccine.
